In millions, except per share items | Jun-30-15 | Mar-31-15 | Dec-31-14 | Sep-30-14 | Jun-30-14 | Mar-31-14 | Dec-31-13 | Sep-30-13 |
| 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
Operating activities | | | | | | | | |
Net loss | -37.2 | -28.8 | -24.2 | -111.4 | -19.5 | -69.4 | -14.0 | -11.5 |
|
Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | | | |
Amortization of premium on marketable securities | 0.2 | 0.2 | | 0.7 | 0.2 | 0.3 | | 0.1 |
Amortization of debt discount and issuance cost | 0.6 | 0.3 | 0.3 | 0.6 | 0.3 | 0.1 | 0.1 | 0.1 |
Depreciation and amortization | 0.4 | | | | 0.0 | | | |
Non-cash in-process research and development | | | | 53.0 | | 53.0 | | |
Stock-based compensation | 6.7 | 4.4 | 3.3 | 9.2 | 3.0 | 2.9 | 1.7 | 2.1 |
Changes in assets and liabilities: | | | | | | | | |
Inventory | -4.0 | | | | | | | |
Prepaid expenses and other current assets | -1.2 | 0.2 | 0.2 | -0.3 | 0.6 | -1.8 | -0.6 | 0.1 |
Restricted cash | | | | 5.1 | 1.2 | 3.9 | 4.6 | 1.5 |
Other assets | 0.0 | 0.0 | 0.4 | -0.8 | -0.9 | | | |
Accounts payable and other accrued liabilities | 9.9 | 1.6 | 3.1 | 1.5 | 0.2 | -1.9 | 0.3 | 1.8 |
Deferred development funds | | | | -2.1 | | -2.1 | -3.0 | -3.9 |
Other liabilities | -0.6 | 0.0 | 0.6 | 0.7 | 0.4 | 0.0 | 0.0 | 0.0 |
Net cash used in operating activities | -25.3 | -21.9 | -15.8 | -43.7 | -14.4 | -15.0 | -10.7 | -9.7 |
|
Investing activities | | | | | | | | |
Purchases of marketable securities | -71.2 | | -7.6 | -33.2 | -13.1 | -9.6 | -31.4 | |
Proceeds from sales of marketable securities | 23.9 | 24.4 | 14.4 | 6.2 | 20.0 | 6.7 | 4.4 | 3.0 |
Proceeds from maturities of marketable securities | 23.9 | 24.4 | 14.4 | 6.2 | 20.0 | 6.7 | 4.4 | 3.0 |
Investment in property and equipment | -0.3 | -0.3 | -0.1 | -1.9 | -0.7 | 0.0 | | |
Other investing activity | 0.5 | | | | | | | |
Net cash (used in) provided by investing activities | -48.1 | 24.2 | 6.7 | -25.0 | 6.2 | -3.0 | -27.1 | 3.0 |
|
Financing activities | | | | | | | | |
Repayment of notes payable | -4.8 | -1.5 | -1.5 | -4.4 | -1.5 | -1.4 | -1.4 | -0.9 |
Proceeds from public offering, net of issuance costs | 134.6 | | | | | | | |
Proceeds from common stock option and warrant exercises | 6.0 | | | | 1.2 | | | |
Net cash (used in) provided by financing activities | -0.1 | 134.3 | -1.4 | -3.1 | -1.3 | -0.3 | 124.1 | -0.7 |
|
Repayment on credit facility | | | | | | | | |
Net (decrease) increase in cash and cash equivalents | -73.6 | 136.6 | -10.5 | -71.8 | -9.6 | -18.3 | 86.3 | -7.4 |
Cash and cash equivalents at beginning of period | | 29.2 | | 111.5 | | 111.5 | | |
Cash and cash equivalents at end of period | -73.6 | 165.9 | -10.5 | 39.7 | -9.6 | 93.2 | 86.3 | -7.4 |
|
Supplemental disclosures | | | | | | | | |
Issuance of common stock to Bayer | | | | 31.4 | | 31.4 | | |
Note payable issued to Bayer at fair value | | | | 21.6 | | 21.6 | | |
Interest expense paid in cash | 1.6 | | 0.1 | 0.6 | 0.4 | | 0.3 | 0.3 |